Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.96USD
6:06pm BST
Change (% chg)

$-0.02 (-0.67%)
Prev Close
$2.98
Open
$2.97
Day's High
$3.01
Day's Low
$2.88
Volume
361,944
Avg. Vol
316,014
52-wk High
$3.86
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Agenus Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Agenus Inc ::AGENUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 EARNINGS PER SHARE $0.14.Q1 REVENUE $80 MILLION.GSK'S SHINGRIX SALES CONTINUE TO GROW; PROJECTED TO BE ABOUT $1.3 BILLION IN 2019.2019 INDS ARE ON TRACK.PARTNERSHIP AND PRIVATE FINANCING DISCUSSIONS ARE UNDERWAY.  Full Article

Gilead Sciences And Agenus Enter Into Collaboration
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Agenus Inc ::GILEAD AND AGENUS ENTER INTO COLLABORATION TO DEVELOP IMMUNO-ONCOLOGY THERAPIES.AGENUS INC - AGENUS WILL RECEIVE $150 MILLION UPON CLOSING.AGENUS INC - AGREEMENT ALSO INCLUDES APPROXIMATELY $1.7 BILLION IN POTENTIAL FUTURE FEES AND MILESTONES.AGENUS INC - GILEAD WILL RECEIVE WORLDWIDE EXCLUSIVE RIGHTS TO AGEN1423, WHICH HAS AN ESTIMATED IND FILING BY YEAR-END 2018.AGENUS INC - GILEAD WILL ALSO RECEIVE EXCLUSIVE OPTION TO LICENSE TWO ADDITIONAL PROGRAMS: AGEN1223 AND AGEN2373..AGENUS INC - AGENUS HAS FILED IND FOR AGEN1223 AND HAS AN ESTIMATED IND FILING FOR AGEN2373 IN FIRST HALF OF 2019..AGENUS INC - AGENUS WILL BE RESPONSIBLE FOR DEVELOPING OPTION PROGRAMS UP TO OPTION DECISION POINTS.  Full Article

Agenus Q3 Loss Per Share $0.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Agenus Inc ::AGENUS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.29.Q3 REVENUE $13 MILLION.PARTNERSHIP DISCUSSIONS PROGRESSING TOWARDS CLOSURE.LEAD IDENTIFIED FOR IND FILING; PRIVATE FINANCING AND PLANS FOR IPO UNDERWAY.  Full Article

Agenus Receives Milestone Payment From Incyte
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Agenus Inc ::AGENUS RECEIVES MILESTONE PAYMENT FROM INCYTE.AGENUS INC - PAYMENT OF $5M RECEIVED FOR INITIATION OF PHASE 1 TRIAL OF LAG-3 ANTIBODY.AGENUS - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $505 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES FROM INCYTE.  Full Article

Agenus Reports Q4 Loss Per Share $0.35
Thursday, 15 Mar 2018 

March 15 (Reuters) - Agenus Inc ::AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.CASH, AND CASH EQUIVALENTS WERE $60.2 MILLION AT DECEMBER 31, 2017.QTRLY REVENUE $8.4 MILLION VERSUS $5.6 MILLION.  Full Article

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Agenus Inc Q2 loss per share $0.32
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Agenus Inc :Agenus reports second quarter 2017 financial results and provides corporate update.Q2 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.32.Cash, cash equivalents and short-term investments were $96.8 million at June 30, 2017 compared to $76.4 million as of december 31, 2016​.Qtrly ‍revenue $ 4.2 million versus $ 6.6 million.Q2 revenue view $5.0 million -- Thomson Reuters I/B/E/S.  Full Article

UPDATE 1-Agenus shares soar after cancer therapy deal with Gilead

Dec 20 Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.